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TAT technology is a biochemical technique for introduction of full-length peptides or proteins
into cells. This process occurs in a rapid, concentration-dependent fashion that appears to be
independent of receptors and transporters. It has broad implications in experimental systems
for regulating intracellular processes and has the potential to be used in the development of
new therapeutic strategies for cancer, infectious diseases, and development of vaccines. It has
been shown that different forms of TAT-p27 protein can modulate the cell cycle of cultured cell
lines, depending on the concentration and type of cells. Transfer of TAT-proteins/peptides use
from cell culture systems to animal disease models has been slow, but the ability of TAT conju-
gates to protect mice against ischemia, inhibit tumor growth, and enhance gene delivery sug-
gests that they offer wide ranging pharmaceutical applications for treating a whole range of
diseases.
Keywords
TAT-vector
protein transduction
drug delivery
CROATICA CHEMICA ACTA
CCACAA 81 (2) 223¿226 (2008)
ISSN-0011-1643
CCA-3234
Review
INTRODUCTION
Different non-biological and biological carrier systems
have been recently developed for delivery of drugs into
cells. Liposomes are excellent potential carriers for some
drugs, antisense oligonucleotides, ribozymes and thera-
peutic genes.1 Nanoparticles and low-density lipoproteins
(LDLs) are cell-specific transporters of drugs against
macrofage-specific infections (HIV1).2 The process of
protein transduction, using the TAT-technology, allows
the delivery of drugs and genetic materials into cells.3,4
A drug development challenge is how to overcome
the unfavourable physicochemical nature of molecules
such as proteins and oligonucleotides, which are unable
to penetrate the cells membrane in order to reach their
intracellular targets. Cell-penetrating peptides have been
developed as a solution to this challenge; once conjugat-
ed to therapeutic molecules, these peptidic sequences fa-
cilitate intracellular delivery. Proteins and peptides are use-
ful research and therapeutic tools; however, their appli-
cations are limited because delivery to the desired loca-
tion is not easily achiveable.5 Penetration into intracel-
lular space can be achieved by adjusting hydrophilicity.
Using this approach, small-molecule-based pharmacolo-
gical agents have been successfully developed. But, it is
difficult to modify hydrophilicity with proteins and pep-
tides without influencing biological functions. TAT-pro-
tein from the human immunodeficiency virus contains a
conserved cationic peptide sequence necessary for trans-
duction across the cell membrane.6 The transduction do-
main from the TAT protein is a good candidate for intra-
cellular delivery of therapeutic macromolecules such as
DNA and proteins. This technique may represent the next
paradigm in the ability to modulate the cell function and
offers a way for better treatment of diseases.
The importance of drug delivery is pivotal in the broad
area of pharmacological research but this issue has not
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been solved to date. The main goal of every drug deli-
very system is the delivery of a precise amount of a drug
to the desired location in order to achieve the drug con-
centration in the targeted organ required for effective treat-
ment.7 The key problem is still how to achieve curative
doses in a pharmacologically active state in the desired
target while avoiding side effect. The currently applied
mechanisms for the transport of therapeutic molecules
across biological membranes are still far from being ef-
ficient.
Cell penetrating peptides or proteins (CPP) offer a
good opportunity for improving intracellular drug deli-
very. They have the ability to cross the plasma membra-
nes of mammalian cells in an apparently energy- and re-
ceptor-independent fashion.8 There is much debate over
the mechanism by which this »protein transduction« oc-
curs. CPPs can be rapidly translocated into cells, being
used to deliver a broad range of therapeutics-including
proteins, DNA, antibodies, oligonucleotides in a variety of
situations and biological systems.8 Moreover, structure-
activity studies indicate that the internalization of CPPs
does not depend on their specific primary sequence, which
implies independence of receptor recognition.9,10 Based
on these results, it has been commonly accepted that the
internalization of CPPs does not involve endocytosis or
specific protein transporters. Instead, direct transport
through the lipid bilayer of membranes has been suggest-
ed as a possible mechanism of translocation.11
Intracellular Delivery by TAT Vector
It is important for intracellular protein delivery to conju-
gate the cargo proteins with a delivery vector (Figure 1).
The HIV1 transcriptional activator TAT is a multifunc-
tional protein that is transported in and out of the cells.12
This cell penetrating property relies on the integrity of a
highly basic arginine-rich sequence (aa 49–58). After
conjugation of TAT peptides with a range of macromole-
cules, it can facilitate cellular entry of the conjugate un-
der in vitro (fluorochromes, enzymes, antibodies and li-
posomes)13–18 and in vivo conditions.19 The procedure of
intracellular delivery is very simple. The conjugates or
fusion proteins bearing a peptide vector are added to the
culture medium to give a final concentration between 0.1
and 10 ìM, in dependence on the cargo. Internalization
is established within 5–30 min in almost all cells. It has
been reported that TAT peptide does not produce any ap-
parent cytotoxicity.20 Using this methodology, various cel-
lular functions have been modulated by introduction of
bioactive proteins into cultured cells. These include mo-
dulation of signal transduction, cell cycles, apoptosis in-
duction, cell migration and proliferation, cytoskeletal re-
organization, etc.20–22 Also, application of this methodo-
logy in in vivo therapy has been reported. Intraperitoneal
injection of a fusion protein of TAT peptides and â-ga-
lactosidase into mice resulted in the delivery of the fusion
protein to various organs (liver, kidney, lung, brain) while
exerting its enzymatic activity.23 Similarly, suppression
of cancer by the delivery of the p53 (Ref. 24) protein and
prevention of ischemic brain injury by administration of
an antiapoptotic Bcl-XL-related protein have been re-
ported.25 Injection of the TAT-Bcl-XL protein decreased
cerebral infarction in a dose dependent manner and al-
tered ischemia-induced caspase-3 activation in ischemic
neurons.26 It was shown on the same model that brain
tissue was progressively transduced with TAT-Bcl-XL with-
in 3–4 h after intravenous delivery and reduced infarct
volume and neurological deficits after long ischemic in-
sults. Further, TAT-Bcl-XL decreased the number of cas-
pase-3-reactive and DNA fragmentized cells and increas-
ed the number of viable neurons in the striatum.27 The
same TAT-Bcl-XL construct, when injected into the eye,
prevented 24 % of mouse retinal ganglion cells from un-
dergoing retrograde neuronal apoptosis caused by an optic
nerve lesion.28 Thus, TAT-fusion proteins could facilitate
protective therapy strategies for neurological disorders.
TAT-technology is also applicable in vaccination strategies.
Viehl et al.29 transduced dendritic cells with TAT-Her2/neu
fusion protein. After intraperitoneal injection of mice,
those cells migrated in all secondary lymphoid organs.
Immunized mice developed palpable tumors much later
than control mice. Similarly, immunized mice had smal-
ler resulting tumors than the control mice.
Mechanism of Cellular Uptake
Facile and efficient delivery of drugs into cells has arous-
ed considerable interest in the internalization mechanism.
Internalization of the TAT and related peptides does not
appear to be dependent on classical endocytosis, cell type,
receptors or active transporters.30 It seems that macropi-
nocytosis is involved in the process of internalization of
TAT fusion proteins.31-35 Macropinocytosis is a pathway
of cellular uptake in which polimerization of actin fila-
ments makes the plasma membrane thrust out of the cell
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Figure 1. Scheme of intracellular delivery of TAT fusion proteins.
surface, resulting in the uptake of extracellular fluid.31 This
procedure is contrary to that of classical clathrin endo-
cytosis, which is initiated by the formation of concave
structures on the plasma membranes. Diameters of clathrin
endosomes are estimated to be less than 120 nm whereas
those of the macropinosomes often exceed 1 mm. This large
size seems a plausible explanation of the cellular uptake
of TAT-fusion proteins/peptides. Cellular uptake of TAT-
fusion proteins is also inhibited in the presence of the
macropinocytosis inhibitor amyloride as well as cyto-
chalasin D, which prevent actin polymerization.31,32 Cell
surface glycosaminoglycans such as heparan sulfate pro-
teoglycan are another factor important for cellular uptake
of arginine peptides (positively charged).35 Electrostatic
interaction of the positively charged peptides and nega-
tively charged proteoglycan will make these peptides
condense on the cell surface, which could eventually ac-
celerate the cellular uptake of these peptides.
TAT Technology in Modulation of Signal
Transduction Pathways
To modulate signal transduction pathways responsible for
proliferation and apoptosis, three forms of protein p27
were transduced into different cell lines.36 Transduction
of TAT-p27 fusion proteins affected the proliferation of
human tumor cell lines, depending on the type of protein
and cell line. It was also shown that some proteins res-
ponsible for the cell cycle regulation were affected. P27
protein as a key regulator of cell cycle progression in-
duced apoptosis in tumor cell lines, in dependence on the
type of cells and the form of p27 protein. The obtained
results seem promising for the use of TAT technology in
treatments of tumors and similar diseases.
CONCLUSIONS
TAT technology has broad implications for experimental
systems and a potential to be used as a delivery tool in
cancer therapy, therapy of infectious diseases, etc. How-
ever, application of peptide and protein based therapeu-
tics still requires a lot of work to be done, specifically in
the fight against cancer and infectious diseases.
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Primjena lijeka pomo}u TAT-tehnologije
Mira Grdi{a i Ana-Matea Mikecin
TAT tehnologija je biokemijska metoda za uno{enje cijelih peptida ili proteina u stanice. Proces ulaska je
vrlo brz, ovisan o koncentraciji, a ~ini se neovisnim o receptorima i transporterima. Ima veliku primjenu u eks-
perimentalnim sustavima za regulaciju stani~nih procesa, a mo`e se tako|er primijeniti u razvoju novih terapij-
skih pristupa lije~enju tumora, infektivnih bolesti te u razvoju vakcina. Pokazalo se da razli~iti oblici fuzijskog
proteina TAT-p27 mogu modulirati stani~ni ciklus humanih tumorskih stanica u kulturi, ovisno o koncentraciji i
tipu stanica. Primjenom TAT-proteina/peptida kod bolesti na `ivotinjskim modelima pokazala se sposobnost
TAT konjugata za za{titu mi{eva od ishemije, inhibiciju rasta tumora i pove}ani unos gena, {to ukazuje da ta
metoda omogu}uje {iroku farmaceutsku primjenu u lije~enju raznih oboljenja.
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